Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Neurosci Lett ; 358(1): 37-40, 2004 Mar 18.
Article in English | MEDLINE | ID: mdl-15016429

ABSTRACT

Riluzole is a presynaptic inhibitor of glutamate release with neuroprotective properties. In order to evaluate the effects of riluzole on motor activity in post-traumatic peripheral neuropathy (PTPN), the sciatic nerve of Wistar male rats was exposed monolaterally and subjected to crushing for one min by a surgical forceps. Animals received an intraperitoneal treatment with riluzole (2, 4 or 8 mg/kg per day), diclofenac (5, 10 or 20 mg/kg) or with vehicle for 3 days. Motor activity and coordination was evaluated in a circular open field and in the rotorod test. The treatment with riluzole stimulated ambulation in PTPN rats and improved their motor performance and coordination. The effect of treatment with riluzole on locomotor activity was greater than that of treatment with diclofenac and was dose-dependent. Furthermore, in contrast to vehicle- and diclofenac-treated rats, animals treated with riluzole showed a long-lasting improvement of locomotor activity as it was assessed 7 days after the end of treatment. These findings suggest that riluzole may improve motor performance in PTPN, and this does not depend on its antinociceptive activity. Its neuroprotective properties are possibly involved in this effect.


Subject(s)
Motor Activity/drug effects , Peripheral Nervous System Diseases/drug therapy , Riluzole/therapeutic use , Sciatic Neuropathy/drug therapy , Animals , Male , Motor Activity/physiology , Peripheral Nervous System Diseases/etiology , Peripheral Nervous System Diseases/physiopathology , Rats , Rats, Wistar , Riluzole/pharmacology , Sciatic Neuropathy/complications , Sciatic Neuropathy/physiopathology
3.
Eur Neuropsychopharmacol ; 12(3): 187-94, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12007669

ABSTRACT

The dopaminergic drugs, ropinirole and dihydroergocryptine (DHECP) were injected subcutaneously (s.c.) at doses of 0.5 and 1 mg/kg/day for 7 days into male rats of the Sprague-Dawley strain. The drug pretreatment reverted amnesia induced in rats by hypobaric hypopxia and tested in active and passive avoidance tasks. Furthermore, a partial restoration of memory retention was found in animals with a 2-month brain occlusive ischemia induced by manipulation of the four major arteries of the brain. No major changes were found in spontaneous motor activity, but drug treatment increased ambulation of animals subjected to acute or chronic experimental manipulation. In a model of kainate-induced epilepsy, ropinirole or DHECP did not affect seizure parameters, but reduced mortality rate. At the end of behavioral procedures, in all animals subjected to hypobaric hypoxia or to brain occlusive ischemia glutathione redox index (glutathione reduced/glutathione oxidized ratio) was measured in the frontal cortex, striatum and hippocampus. It was found that experimental models of brain injury were followed by a decrease of reduced glutathione content in all brain areas. The glutathione redox index was augmented by ropinirole or DHECP treatment in all brain areas. These behavioral and neurochemical findings suggest that ropinirole and DHECP may exert either protective activity (as found in animals pretreated with these drugs and exposed to hypobaric hypoxia) or reversal of brain injury (as found in animals treated after two-month occlusive brain ischemia). Thus, both drugs may be studied as therapeutic agents in brain injuries of various origin.


Subject(s)
Behavior, Animal/drug effects , Brain Injuries/drug therapy , Disease Models, Animal , Dopamine Agonists/pharmacology , Dopamine Agonists/therapeutic use , Animals , Behavior, Animal/physiology , Brain/drug effects , Brain/metabolism , Brain Injuries/metabolism , Dihydroergocryptine/pharmacology , Dihydroergocryptine/therapeutic use , Dopamine Agents/pharmacology , Dopamine Agents/therapeutic use , Glutathione/metabolism , Indoles/pharmacology , Indoles/therapeutic use , Male , Rats , Rats, Sprague-Dawley
4.
Neurosci Lett ; 300(3): 176-8, 2001 Mar 16.
Article in English | MEDLINE | ID: mdl-11226639

ABSTRACT

Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis. Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg). Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found. In particular, low doses reduced the latency to and prolonged the duration of barbiturate narcosis. In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate. Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis. Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.


Subject(s)
Antioxidants/pharmacology , Melatonin/pharmacology , Sleep/drug effects , Unconsciousness/drug therapy , Adjuvants, Anesthesia/pharmacology , Anesthetics, Dissociative/pharmacology , Animals , Antioxidants/administration & dosage , Barbiturates , Diazepam/pharmacology , Dose-Response Relationship, Drug , Ketamine/pharmacology , Male , Melatonin/administration & dosage , Rats , Rats, Wistar , Sleep/physiology , Unconsciousness/chemically induced , Unconsciousness/mortality
SELECTION OF CITATIONS
SEARCH DETAIL
...